Irene Zubiri
Research Subjects
Research Interests
Irene Zubiri has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Andrea Malaspina
Department of Neuromuscular Diseases, UCL Queen Square Motor Neuron Disease Center, UCL Queen Square Institute of Neurology, University College London, London, UK
1 shared publication - Ching-Hua Lu1 shared publication
- Emanuela Leoni
Proteome Sciences
1 shared publication - Hui-Chung Liang
Proteome Sciences plc , Coveham House, Downside Bridge Road, Cobham KT11 3EP, United Kingdom
1 shared publication - Ian Pike
Proteome Sciences
1 shared publication - Johan Aarum
Karolinska University Hospital
1 shared publication
Latest Publications
- Open Access
- 19 December 2016
- Published by F1000 Research Ltd
- Vol. 5
Tissue-enhanced proteomic analysis of plasma samples reveals new mechanistic biomarker candidates for the stratification of Amyotrophic lateral sclerosis patients
Background. Early diagnosis and patient stratification in ALS based on disease sub-type and progression rate requires the ability to measure objectively the molecular changes underlying the development of disease. The simultaneous analysis of diseased tissues and biological fluids using a powerful and revolutionary proteomic technique called TMTcalibrator™, enhances detection of low-abundant, tissue-derived proteins that reflect the central disease processes in the periphery. These are powerful biomarkers that should lead to a better clinical stratification of ALS patients. Objectives. To co-analyse the plasma and peripheral blood mononuclear cell proteomes from patients with different forms and rates of progression of ALS and equivalent mouse models to identify co-expressed proteins, which are differentially regulated at different stages of disease and may serve as useful stratification biomarkers. Methods. TMTcalibrator™ was employed to enhance detection of disease-associated plasma proteins. PBMC digests were used as the calibrator, spiked in a 1.75:1 excess to plasma samples from patients stratified according to progression rate and disease stage. Six patients with a slow progression rate (monthly slope of ALSRS-R from disease onset to last visit or progression rate to last visit, PRL1) were studied. For each patient, two plasma samples were included in the study from an early (ALSRS-R (/48) >40) and a late disease stage (ALSRS-R (/48) <30.) An equivalent study was performed in PBMCS/plasma from mouse models reproducing a similar fast and slow disease progression. Results. We have identified approximately 4500 unique proteins in each data set. We first analysed data by time point to identify 95 differentially regulated proteins between slow and fast progressors in early samples, and 107 significantly regulated proteins in late stage samples. When considering slow and fast progressing patients separately, 625 proteins (259 unique, 366 shared) were differentially expressed between early and late samples for the slow progressing patients and 525 (159 unique, 366 shared) for the fast progressing patients. Functional annotation was performed to extract relevant biological interpretation in the context of known mechanisms of ALS. In silico comparisons of these results with those obtained from the mouse models have also been performed to highlight those proteins that are detected as regulated in both species. Discussion and conclusions. This is the deepest proteomic profiling yet undertaken on plasma from ALS patients. The TMTcalibrator™ technique has provided a unique opportunity to study the interface between cellular and fluid components of blood in unravelling of ALS pathology. The parallel analysis of mouse models recapitulating a similar heterogeneity of the disease will provide a formidable working platform with translational potential and a dataset to support researchers working in ALS. Acknowledgements. We are grateful to the Motor Neurone Disease Association and The Wellcome Trust for support.
- 19 December 2016
- Published by F1000 Research Ltd
- Vol. 5
Open AccessTissue-enhanced proteomic analysis of plasma samples reveals new mechanistic biomarker candidates for the stratification of Amyotrophic lateral sclerosis patients
Background. Early diagnosis and patient stratification in ALS based on disease sub-type and progression rate requires the ability to measure objectively the molecular changes underlying the development of disease. The simultaneous analysis of diseased tissues and biological fluids using a powerful and revolutionary proteomic technique called TMTcalibrator™, enhances detection of low-abundant, tissue-derived proteins that reflect the central disease processes in the periphery. These are powerful biomarkers that should lead to a better clinical stratification of ALS patients. Objectives. To co-analyse the plasma and peripheral blood mononuclear cell proteomes from patients with different forms and rates of progression of ALS and equivalent mouse models to identify co-expressed proteins, which are differentially regulated at different stages of disease and may serve as useful stratification biomarkers. Methods. TMTcalibrator™ was employed to enhance detection of disease-associated plasma proteins. PBMC digests were used as the calibrator, spiked in a 1.75:1 excess to plasma samples from patients stratified according to progression rate and disease stage. Six patients with a slow progression rate (monthly slope of ALSRS-R from disease onset to last visit or progression rate to last visit, PRL1) were studied. For each patient, two plasma samples were included in the study from an early (ALSRS-R (/48) >40) and a late disease stage (ALSRS-R (/48) <30.) An equivalent study was performed in PBMCS/plasma from mouse models reproducing a similar fast and slow disease progression. Results. We have identified approximately 4500 unique proteins in each data set. We first analysed data by time point to identify 95 differentially regulated proteins between slow and fast progressors in early samples, and 107 significantly regulated proteins in late stage samples. When considering slow and fast progressing patients separately, 625 proteins (259 unique, 366 shared) were differentially expressed between early and late samples for the slow progressing patients and 525 (159 unique, 366 shared) for the fast progressing patients. Functional annotation was performed to extract relevant biological interpretation in the context of known mechanisms of ALS. In silico comparisons of these results with those obtained from the mouse models have also been performed to highlight those proteins that are detected as regulated in both species. Discussion and conclusions. This is the deepest proteomic profiling yet undertaken on plasma from ALS patients. The TMTcalibrator™ technique has provided a unique opportunity to study the interface between cellular and fluid components of blood in unravelling of ALS pathology. The parallel analysis of mouse models recapitulating a similar heterogeneity of the disease will provide a formidable working platform with translational potential and a dataset to support researchers working in ALS. Acknowledgements. We are grateful to the Motor Neurone Disease Association and The Wellcome Trust for support.
- Open Access
- 16 December 2016
- Published by F1000 Research Ltd
- Vol. 5
Isolation and characterisation of circulating neurofilament-containing aggregates in health and disease
BACKGROUND: There are currently no accurate diagnostic or prognostic tools for ALS, resulting in delayed diagnosis and poor disease stratification. Although the aetiology of ALS is still unknown, a hallmark of this neurological condition is the presence of protein aggregates within neurons (1). In addition, ALS and other neurodegenerative diseases are associated with a compromised blood brain barrier (BBB), resulting in leakage of brain-derived proteins into plasma (2). Thus, plasma could represent a readily accessible source of diagnostic and prognostic biomarkers. We and others have shown that Neurofilaments (NFs) in cerebrospinal fluid (CSF) and plasma are a promising ALS biomarker, but suffer from high variability within and between patients. Interestingly, our data suggest that this could in part be due to epitope masking caused by protein aggregation. We propose that these circulating NF aggregates will have multiple protein components, reflecting both mechanistic and random associations. Thus, the identification of these aggregate components may provide a source of sensitive and specific biomarkers for the early diagnosis and prognostic monitoring of ALS patients. OBJECTIVES: To develop and validate a method for the isolation of circulating blood protein aggregates and to characterise the composition of these aggregates by Mass Spectrometry (MS) based Proteomics. METHODS: In order to establish the best isolation method, a Pooled Plasma sample (PP) has been created using plasma from six Healthy Controls between 51.2-62.9 years of age and with known blood level of NF heavy chain (between 7.0 and 42.9ng/ml). Two different conditions for aggregate isolation have been evaluated, Sedimentation velocity and Seprion TM ligand interaction. RESULTS: Western blot (WB) showed a detectable amount of NFs in the aggregate fractions. Tandem MS data showed the presence of 651 and 1068 proteins (Protein Grouping: True; Peptide Confidence: High; Minimal number of peptides: 1) for the sedimentation and ligand methods, respectively. 380 common proteins were found between the two methods. DISCUSSION: We showed that sedimentation is a good methodology for isolation of aggregates circulating in blood. The detection of high molecular weight bands by WB suggests the presence of aggregates containing NFs in our pellets. Also, from proteomics data it is clear that these two methods isolate cytoskeletal and other intracellular proteins, potential allowing the detection of CNS derived material. Further analysis is ongoing to evaluate the best methods for isolation and analysis. AKNOLEDGMENTS: This project is funded by an MRC-Industry CASE Studentship. Plasma samples obtained from study 09/H0703/27. REFERENCES: Blokhuis AM, Groen EJ, Koppers M, van den Berg LH, Pasterkamp RJ. Protein aggregation in amyotrophic lateral sclerosis. Acta neuropathologica. 2013;125(6):777-94. Garbuzova-Davis S, Hernandez-Ontiveros DG, Rodrigues MC, Haller E, Frisina-Deyo A, Mirtyl S, et al. Impaired blood-brain/spinal cord barrier in ALS patients. Brain research. 2012;1469:114-28.
- 16 December 2016
- Published by F1000 Research Ltd
- Vol. 5
Open AccessIsolation and characterisation of circulating neurofilament-containing aggregates in health and disease
BACKGROUND: There are currently no accurate diagnostic or prognostic tools for ALS, resulting in delayed diagnosis and poor disease stratification. Although the aetiology of ALS is still unknown, a hallmark of this neurological condition is the presence of protein aggregates within neurons (1). In addition, ALS and other neurodegenerative diseases are associated with a compromised blood brain barrier (BBB), resulting in leakage of brain-derived proteins into plasma (2). Thus, plasma could represent a readily accessible source of diagnostic and prognostic biomarkers. We and others have shown that Neurofilaments (NFs) in cerebrospinal fluid (CSF) and plasma are a promising ALS biomarker, but suffer from high variability within and between patients. Interestingly, our data suggest that this could in part be due to epitope masking caused by protein aggregation. We propose that these circulating NF aggregates will have multiple protein components, reflecting both mechanistic and random associations. Thus, the identification of these aggregate components may provide a source of sensitive and specific biomarkers for the early diagnosis and prognostic monitoring of ALS patients. OBJECTIVES: To develop and validate a method for the isolation of circulating blood protein aggregates and to characterise the composition of these aggregates by Mass Spectrometry (MS) based Proteomics. METHODS: In order to establish the best isolation method, a Pooled Plasma sample (PP) has been created using plasma from six Healthy Controls between 51.2-62.9 years of age and with known blood level of NF heavy chain (between 7.0 and 42.9ng/ml). Two different conditions for aggregate isolation have been evaluated, Sedimentation velocity and Seprion TM ligand interaction. RESULTS: Western blot (WB) showed a detectable amount of NFs in the aggregate fractions. Tandem MS data showed the presence of 651 and 1068 proteins (Protein Grouping: True; Peptide Confidence: High; Minimal number of peptides: 1) for the sedimentation and ligand methods, respectively. 380 common proteins were found between the two methods. DISCUSSION: We showed that sedimentation is a good methodology for isolation of aggregates circulating in blood. The detection of high molecular weight bands by WB suggests the presence of aggregates containing NFs in our pellets. Also, from proteomics data it is clear that these two methods isolate cytoskeletal and other intracellular proteins, potential allowing the detection of CNS derived material. Further analysis is ongoing to evaluate the best methods for isolation and analysis. AKNOLEDGMENTS: This project is funded by an MRC-Industry CASE Studentship. Plasma samples obtained from study 09/H0703/27. REFERENCES: Blokhuis AM, Groen EJ, Koppers M, van den Berg LH, Pasterkamp RJ. Protein aggregation in amyotrophic lateral sclerosis. Acta neuropathologica. 2013;125(6):777-94. Garbuzova-Davis S, Hernandez-Ontiveros DG, Rodrigues MC, Haller E, Frisina-Deyo A, Mirtyl S, et al. Impaired blood-brain/spinal cord barrier in ALS patients. Brain research. 2012;1469:114-28.